Holmøy, Trygve https://orcid.org/0000-0002-2529-5664
Høglund, Rune Alexander
Illes, Zsolt
Myhr, Kjell-Morten
Torkildsen, Øivind
Funding for this research was provided by:
University of Oslo
Article History
Received: 14 July 2020
Revised: 16 September 2020
Accepted: 17 September 2020
First Online: 3 October 2020
Compliance with ethical standards
:
: Trygve Holmøy has received speakers’ honoraria and/or unrestricted research grants from Biogen, Roche, Sanofi and Merck, and has been principal investigator in studies sponsored by Biogen, Merck and Roche. Rune A. Høglund has received speakers’ honoraria and/or unrestricted grants from Biogen, Merck, Roche and Novartis, and participated as investigator in study sponsored by Roche. Zsolt Illes has received speakers’ honoraria and/or research grants from Biogen, Roche, Sanofi, Novartis and Merck, has been member of advisory boards at Alexion, Biogen, Sanofi, Merck, Roche, Novartis, was member of the adjudication relapse committee in the SAkuraStar and SAkuraSky trials, and has been principal investigator in studies sponsored by Biogen, Merck and Sanofi. Øivind Torkildsen has received speakers’ honoraria and/or unrestricted research grants from Biogen, Roche, Novartis, Merck and Sanofi and has been principal investigator in studies sponsored by Sanofi. Kjell-Morten Myhr has received unrestricted research grants to his institution; scientific advisory board, and speakers’ honoraria from Almirall, Biogen, Genzyme, Merck, Novartis, Roche, or Teva; and has participated in clinical trials organized by Biogen, Merck, Novartis, or Roche.
: Not applicable.
: Not applicable.
: Consent to publish the figures has been granted by Kari C Toverud.